Drug Profile
Research programme: cancer therapy companion diagnostic - Amgen/Dako
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen; Dako A/S
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Diagnosis) in Denmark
- 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
- 10 Jan 2012 Early research in Cancer (Diagnosis) in Denmark (unspecified route)